DR. LASIKA CHANDRADATTA SENEVIRATNE M.D.
NPI 1437268174
Internal Medicine - Hematology & Oncology in Los Angeles, CA

Active since August 29, 2006PECOS EnrolledAccepts Medicare Assignment
100/100
CMS Quality Rating
1245 WILSHIRE BLVD, SUITE 303, LOS ANGELES, CA 90017(213) 977-1214(213) 482-8868 Get Directions Write a Review

NPPES record last updated: March 13, 2020. Verified against the NPPES registry weekly; last sync: August 02, 2026.

Record update history: Mar 13, 2020, Oct 18, 2019, Mar 19, 2018 (3 updates tracked since 2018).

About Dr. Lasika Chandradatta Seneviratne M.d. NPPES

Official registry information on file with the National Plan and Provider Enumeration System.

DR. LASIKA CHANDRADATTA SENEVIRATNE M.D. (NPI 1437268174) is an individual hematology & oncology provider in Los Angeles, California, licensed in California (A56331) and active in the NPI registry since August 2006. He is enrolled in Medicare PECOS and is a graduate of Other (1992).

NPPES Registry Identity

NPI1437268174
Entity TypeIndividualMale
Primary Taxonomy207RH0003X
Provider Legal NameDR. LASIKA CHANDRADATTA SENEVIRATNECredential: M.D.
Location Address1245 WILSHIRE BLVD, SUITE 303Los Angeles, CA 90017-4810
Mailing Address541 W Colorado St Ste 205Glendale, CA 91204-3640 · (323) 254-0046 · Fax (323) 488-9782
Fax(213) 482-8868
Sole ProprietorNo
Medical School CMSOtherGraduated 1992
Enumeration DateAugust 29, 2006
Last NPPES UpdateMarch 13, 20203 updates tracked since enumeration
NPPES CertifiedMarch 13, 2020
NPI 1437268174 is a valid, active identifier and passes the ISO check-digit test.

Specialties & Licenses

Primary SpecialtyInternal Medicine · Hematology & OncologyAllopathic & Osteopathic Physicians
Taxonomy Code207RH0003X
License Licensed in CA · A56331
Definition
An internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered.
1245 WILSHIRE BLVD, Los Angeles, CA 90017

Other Identifiers 2

Medicaid00A563310CA
OtherA056331CA · Ca Medical License

Medicare Participation & PECOS CMS

Medicare enrollment, assignment, and ordering and referring status from the CMS PECOS system.

Medicare Enrollment Status

Enrolled in Medicare and accepts Medicare assignment

Dr. Lasika Chandradatta Seneviratne M.d. is registered in PECOS and agrees to accept the Medicare-approved amount as full payment. Medicare patients are not billed beyond the standard deductible and coinsurance.

PECOS PAC ID7416860267
PECOS Enrollment IDI20031230000413
Eligible to Order & Refer Part B Labs & Imaging Durable Medical Equipment Home Health Agency Power Mobility DevicesPer the CMS Ordering and Referring file. Eligibility means Medicare pays claims that this provider orders or refers for these categories.

Areas of Expertise CMS Part B claims 30

Services this provider delivered to Medicare fee-for-service patients, from the CMS Medicare utilization data. Higher counts generally reflect more experience with a service; care delivered outside Medicare is not included.

Injection, denosumab, 1 mg J0897
Denosumab is a medication given via injection to strengthen your bones. It works by slowing down the cells that break down bone, improving bone density and reducing the risk of fractures. It's often used for osteoporosis treatment.
6,674 services47 patients
Injection, dexamethasone sodium phosphate, 1 mg J1100
Dexamethasone sodium phosphate is a medication given via injection. It is a type of steroid that helps reduce inflammation and immune responses. It can be used to treat a variety of conditions, such as allergies, skin conditions, arthritis, and more.
2,671 services39 patients
Injection, ferric derisomaltose, 10 mg J1437
Ferric derisomaltose is an iron replacement product. It's given as an injection to treat iron deficiency anemia, a condition where the body lacks enough iron. The injection helps increase iron in your body to healthy levels.
1,800 services18 patients
Injection, heparin sodium, (heparin lock flush), per 10 units J1642
Heparin sodium injection, often referred to as a heparin lock flush, is a procedure used to prevent blood clots in the veins. It involves injecting a small amount of heparin, a blood-thinning medication, into an intravenous (IV) line to keep it open and prevent blockages.
1,360 services17 patients
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885
Epoetin alfa is a medication injected to help your body produce more red blood cells, improving energy levels and reducing tiredness. It's often used for patients with certain types of anemia. Each injection contains 1000 units of the medicine.
975 services13 patients
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more 99214
This is a routine check-up for patients who have previously visited our clinic. It involves a comprehensive review of your health and any ongoing treatments. The consultation lasts between 30-39 minutes, allowing enough time to discuss any concerns.
945 services205 patients

Physician Visit Costs CMS claims · ZIP area

Typical Medicare office-visit costs in the 90017 ZIP code area, from fee-for-service claims. These are area statistics, not this provider’s prices; actual charges vary by service and coverage.

New Patient
$187.60 typical visit price
range $62.96 – $187.60
Typical copayment $46.90 (range $15.74 – $46.90)
Most-billed visit code 99205
Established Patient
$109.96 typical visit price
range $20.84 – $153.61
Typical copayment $27.49 (range $5.21 – $38.40)
Most-billed visit code 99214
Amounts reflect what Medicare beneficiaries in this ZIP area are typically charged for office visits. Patients with other coverage should check their individual plans.

Medicare Quality Performance CMS QPP · MIPS

Performance in the CMS Quality Payment Program: the MIPS final score across four weighted categories, and the individual quality measures reported to Medicare.

100/100
MIPS Final ScoreMerit-based Incentive Payment System · CMS Quality Payment Program
Scored as part of a group practice
Quality93.72
Improvement Activities40

Reported Quality Measures

Advance Care Plan
92%601 patients4/55-star benchmark: 100%
Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer
100%36 patients
Breast Cancer Screening
0%509 patients1/55-star benchmark: 93%
Colorectal Cancer Screening
4%792 patients1/55-star benchmark: 88%
Documentation of Current Medications in the Medical Record
90%5,858 patients4/55-star benchmark: 100%
Oncology: Medical and Radiation - Pain Intensity Quantified
97%1,959 patients4/55-star benchmark: 100%
Oncology: Medical and Radiation - Plan of Care for Pain
82%491 patients3/55-star benchmark: 100%
Preventive Care and Screening: Screening for Depression and Follow-Up Plan
89%1,242 patients4/55-star benchmark: 97%
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Patients combinedPopulations: 99% · 1,149 patients
Patients screened: 100% · 1,149 patients
77%53 patients4/55-star benchmark: 100%
Providers report different measures because they deliver different services; reporting more or less information is not a reflection of quality. Star ratings appear only where CMS assigned them.

Referred Medical Equipment & Supplies CMS DME claims 3

Durable medical equipment, devices and supplies this provider ordered from DME suppliers for patients, from Medicare fee-for-service claims.

Capecitabine, oral, 500 mg J8521
Treatment-Treatment - Miscellaneous · category RX029N
1 supplier34 claims2,408 services$0.72 avg. paid by Medicare
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period Q0511
Treatment-Chemotherapy · category RH012N
1 supplier22 claims22 services$18.09 avg. paid by Medicare
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period Q0512
Treatment-Chemotherapy · category RH012N
1 supplier12 claims12 services$12.62 avg. paid by Medicare
Dollar amounts are the average Medicare paid the supplier per service. They are not the cost to the patient.

Other Providers at the Same Location NPPES 20

Providers registered at the same practice address, or within the immediate area, according to the NPPES registry.

Psychiatry & Neurology (Neurology)
1245 WILSHIRE BLVD, SUITE 814
LOS ANGELES, CA 90017
Ophthalmology
1245 WILSHIRE BLVD, 380
LOS ANGELES, CA 90017
Internal Medicine
1245 WILSHIRE BLVD, SUITE 790
LOS ANGELES, CA 90017
Internal Medicine (Hematology & Oncology)
1245 WILSHIRE BLVD, SUITE 801
LOS ANGELES, CA 90017
Internal Medicine
1245 WILSHIRE BLVD, STE 307
LOS ANGELES, CA 90017
Specialist
1245 WILSHIRE BLVD, SUITE 905
LOS ANGELES, CA 90017
Internal Medicine (Pulmonary Disease)
1245 WILSHIRE BLVD, SUITE 407
LOS ANGELES, CA 90017
Ophthalmology
1245 WILSHIRE BLVD, 380
LOS ANGELES, CA 90017

Frequently Asked Questions NPPES & CMS

Common questions about this NPI record, answered from the official NPPES registry and CMS datasets shown on this page.

What is Lasika Seneviratne's NPI number?

The NPI number for Lasika Seneviratne is 1437268174. It was assigned to this individual provider in the NPPES registry on August 29, 2006.

Where is Lasika Seneviratne located?

Lasika Seneviratne practices at 1245 Wilshire Blvd Suite 303, Los Angeles, CA 90017. The listed phone number is (213) 977-1214.

What is Lasika Seneviratne's specialty?

The primary specialty registered for this NPI is Internal Medicine, specializing in Hematology & Oncology, with taxonomy code 207RH0003X.

Is Lasika Seneviratne enrolled in Medicare?

Yes. Lasika Seneviratne is registered in the Medicare PECOS system and accepts Medicare assignment, which means accepting the Medicare-approved amount as payment in full for covered services.

When was this NPI record last updated?

The NPPES record for Lasika Seneviratne was last updated on March 13, 2020. NPI Profile syncs weekly with the NPPES registry data releases published by CMS. This NPI record was last updated 6 years ago. If this record has changed at CMS more recently, you can request an on-demand re-check against the live CMS registry, directly from this page.